RJA
INSM icon

Raymond James & Associates’s Insmed INSM Stock Holding History

Raymond James & Associates’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$5.56M Buy
76,232
+11,288
+17% +$833K ﹤0.01% 1591
2024
Q2 		$4.35M Buy
64,944
+2,943
+5% +$114K ﹤0.01% 1681
2024
Q1 		$1.68M Buy
62,001
+20,885
+51% +$584K ﹤0.01% 2271
2023
Q4 		$1.27M Sell
41,116
-3,098
-7% -$80.3K ﹤0.01% 2375
2023
Q3 		$1.12M Buy
44,214
+12,573
+40% +$288K ﹤0.01% 2387
2023
Q2 		$668K Sell
31,641
-692
-2% -$13.1K ﹤0.01% 2741
2023
Q1 		$551K Buy
32,333
+4,542
+16% +$88.2K ﹤0.01% 2861
2022
Q4 		$555K Buy
27,791
+6,131
+28% +$119K ﹤0.01% 2826
2022
Q3 		$467K Buy
21,660
+850
+4% +$20.4K ﹤0.01% 2910
2022
Q2 		$410K Sell
20,810
-77
-0.4% -$1.61K ﹤0.01% 3032
2022
Q1 		$491K Sell
20,887
-284
-1% -$6.6K ﹤0.01% 3088
2021
Q4 		$577K Sell
21,171
-791
-4% -$22.6K ﹤0.01% 2983
2021
Q3 		$605K Sell
21,962
-1,072
-5% -$28.1K ﹤0.01% 2925
2021
Q2 		$656K Buy
23,034
+742
+3% +$22K ﹤0.01% 2885
2021
Q1 		$759K Sell
22,292
-576
-3% -$22K ﹤0.01% 2697
2020
Q4 		$761K Sell
22,868
-651
-3% -$23.8K ﹤0.01% 2523
2020
Q3 		$756K Buy
23,519
+519
+2% +$14.9K ﹤0.01% 2349
2020
Q2 		$633K Buy
23,000
+5,869
+34% +$139K ﹤0.01% 2442
2020
Q1 		$275K Sell
17,131
-178,518
-91% -$4.23M ﹤0.01% 2829
2019
Q4 		$4.67M Buy
195,649
+18,419
+10% +$375K 0.01% 1296
2019
Q3 		$3.13M Buy
177,230
+34,933
+25% +$675K ﹤0.01% 1522
2019
Q2 		$3.64M Buy
142,297
+39,976
+39% +$1.11M 0.01% 1423
2019
Q1 		$2.97M Buy
102,321
+44,564
+77% +$1.15M ﹤0.01% 1514
2018
Q4 		$758K Buy
57,757
+29,150
+102% +$465K ﹤0.01% 2258
2018
Q3 		$578K Buy
+28,607
New +$646K ﹤0.01% 2612

Other funds holding INSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Raymond James & Associates's INSM Position: Q3 2024 in Review

Raymond James & Associates increased its Insmed (INSM) stake by 17% in Q3 2024, buying an estimated $833K and bringing the position to 76,232 shares worth $5.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1591.

Raymond James & Associates first reported a position in INSM in Q3 2018 and has held it in 25 quarters since. 413 funds tracked by Wall St. Rank hold INSM as of Q3 2024.

  • Raymond James & Associates held 76,232 shares of Insmed worth $5.56M as of Q3 2024.
  • Raymond James & Associates bought 11,288 Insmed shares in Q3 2024, an estimated $833K.
  • Insmed made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1591 holding.
  • Raymond James & Associates first reported a position in Insmed in Q3 2018 and has held it in 25 quarters since.
  • 413 funds tracked by Wall St. Rank held Insmed as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.